Premaitha Health plc
(“Premaitha” or the “Group”)
Change of Name to Yourgene Health plc
Change of Website Address
Manchester, UK – 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc (“Yourgene Health”).
Further to the special resolution approved at the Group’s Annual General Meeting on 25 October 2018, the Group’s name has been changed to Yourgene Health plc and trading in the Group’s shares under the new name and TIDM, “YGEN”, will commence at 8.00 a.m. today. The Group’s website is now available at www.yourgene-health.com.
The change of name reflects the Group’s broadened product development and research service capabilities which extend across the lifecycle of DNA test development and commercialisation.
Yourgene Health’s ongoing strategic priorities include:
• developing and commercialising genetic products and services that positively impact human health;
• driving worldwide sales of the Group’s non-invasive prenatal testing (“NIPT”) products and services by targeting further expansion through direct and key distribution channels to expand the geographic footprint;
• continuing to offer highly customer-focused NIPT products and services which support all types of customer - irrespective of size, geography and market maturity - in partnership with leading DNA technology providers;
• leveraging the Group’s technical and regulatory expertise and partnerships to extend its genetic testing offering into complementary areas of reproductive health and oncology, both with owned intellectual property and as a third-party collaborator; and
• supporting diagnostic majors and bioinformatics specialists with in vitro diagnostic product contract development partnerships.
Shareholdings will be unaffected by the change of name and existing share certificates should be retained as they will remain valid for all purposes. Any new share certificates issued will bear the name Yourgene Health plc.
Lyn Rees, Chief Executive Officer of Yourgene Health, commented: “Our change of name to Yourgene Health marks the beginning of an exciting new period for the Group. It reflects our broadened capabilities within the genetic testing universe and the combining of the Premaitha and Yourgene Bioscience businesses.
“Within the NIPT segment, we are aggressively targeting further expansion through distribution and licensing partnerships. The consolidated Group is now well-placed to deliver services to a global market and maximise its revenue potential.
“Our technical expertise in genetic test development, partnerships with DNA technology majors and expanding global footprint also put us in a strong position to develop additional products both within reproductive health and oncology.
“I look forward to providing further updates on the commercialisation of the Group as we expand organically, through distribution and licensing agreements, and via third party partnerships.”
For more information, please contact:
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
Tel: +44 (0)161 667 1053
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie
Tel: +44 (0)20 7213 0880
Geoff Nash / Matthew Radley (Corporate Finance)
Tim Redfern (Corporate Broking)
Tel: +44 (0)20 7220 0500
Ben Simons / Fiona Henson / Antonia Pollock
Tel: +44 (0)20 7390 0234
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services that positively impact human health. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Our product development and research service capabilities extend across the lifecycle of DNA test development including regulatory submissions.
Yourgene Health’s first commercialised products are non-invasive prenatal tests (NIPT) for Down’s syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.
Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Yourgene Health’s customer-focused products and services support all types of customer, irrespective of size, geography and market maturity. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.